Last updated: June 27, 2026
Puma Biotechnology v. AstraZeneca (1:21-cv-01338) Patent Litigation Summary: What Claims Were Asserted, What Happened Procedurally, and What the Outcome Means
Puma Biotechnology, Inc. v. AstraZeneca Pharmaceuticals LP (D. Del., No. 1:21-cv-01338) is a patent-infringement case filed by Puma against AstraZeneca tied to AstraZeneca’s oncology asset obligations under the Hatch-Waxman framework. The matter’s key business relevance is whether Puma’s asserted patent(s) block or delay FDA approval of a competing product, and whether the court’s disposition creates a practical licensing or non-infringement safe harbor for AstraZeneca and its manufacturing or commercial partners.
No litigation outcome, asserted patent numbers, claim constructions, summary-judgment holdings, trial rulings, or settlement terms are provided in the input. Under the operating constraints, a complete and accurate litigation summary cannot be produced.
What patents did Puma assert in AstraZeneca Pharmaceuticals LP case 1:21-cv-01338?
Answer: Not available from the provided information.
Which patent numbers are at issue in 1:21-cv-01338?
Not available from the provided information.
What drug/product is linked to the asserted patents?
Not available from the provided information.
What patents did AstraZeneca counter with in Puma v. AstraZeneca 1:21-cv-01338?
Answer: Not available from the provided information.
Did AstraZeneca challenge validity or enforceability?
Not available from the provided information.
Did AstraZeneca argue non-infringement on claim scope or product equivalence?
Not available from the provided information.
What is the procedural timeline for Puma Biotechnology v. AstraZeneca 1:21-cv-01338?
Answer: Not available from the provided information.
Filing, service, and initial responsive pleadings
Not available from the provided information.
Key motions (dismissal, venue, pleadings sufficiency)
Not available from the provided information.
Markman or claim construction milestones
Not available from the provided information.
Summary judgment and dispositive rulings
Not available from the provided information.
Trial and post-trial orders
Not available from the provided information.
How did the court rule in Puma v. AstraZeneca Pharmaceuticals LP 1:21-cv-01338 (dismissed, summary judgment, or settlement)?
Answer: Not available from the provided information.
Was the case dismissed (with or without prejudice)?
Not available from the provided information.
Did the court grant summary judgment of non-infringement or invalidity?
Not available from the provided information.
Was there a settlement agreement, consent judgment, or stipulated dismissal?
Not available from the provided information.
What Paragraph IV and Orange Book events are tied to Puma v. AstraZeneca 1:21-cv-01338?
Answer: Not available from the provided information.
Which FDA NDA/ANDA/BLA and Orange Book listing triggered the suit
Not available from the provided information.
What was the FDA procedural posture during litigation (pending approval, approvable letter, tentative approval)
Not available from the provided information.
Which companies are involved and how do litigation roles map to product development and manufacturing risk?
Answer: Not available from the provided information.
Defendants, counter-parties, and related AstraZeneca entities
Not available from the provided information.
Puma’s portfolio or licensing positions reflected in the complaint
Not available from the provided information.
How strong is Puma’s patent estate relative to AstraZeneca’s freedom-to-operate in 1:21-cv-01338?
Answer: Not available from the provided information.
Claim breadth, prosecution history, and prior art signals
Not available from the provided information.
Validity risk factors (anticipation, obviousness, written description, enablement)
Not available from the provided information.
What generic entry risks does Puma v. AstraZeneca 1:21-cv-01338 create?
Answer: Not available from the provided information.
Launch timing impact and exclusivity leverage
Not available from the provided information.
Design-around pathways suggested by claim scope
Not available from the provided information.
How does the Puma v. AstraZeneca litigation affect biosimilar or biologics risk (if applicable)?
Answer: Not available from the provided information.
Whether the case is about small molecules, biologics, or delivery system changes
Not available from the provided information.
Key Takeaways
Not available from the provided information.
FAQs
-
Was Puma’s case in 1:21-cv-01338 filed as a Paragraph IV infringement action under 35 U.S.C. § 271(e)(2)?
Not available from the provided information.
-
Which specific asserted claims and products were central to the infringement theory?
Not available from the provided information.
-
Did the court issue a Markman ruling that narrowed claim scope?
Not available from the provided information.
-
What was the final disposition of the case in 1:21-cv-01338?
Not available from the provided information.
-
How does the outcome influence FDA approval timing for AstraZeneca’s product and any potential generic entry?
Not available from the provided information.
References (APA)
Not available from the provided information.
